What is BIOLASE's stock price target for 2024?

0 equities research analysts have issued 1 year target prices for BIOLASE's stock. Their BIOL share price targets range from $4.00 to $150.00. On average, they anticipate the company's stock price to reach $77.00 in the next year. This suggests a possible upside of 53,446.6% from the stock's current price. View analysts price targets for BIOL or view top-rated stocks among Wall Street analysts .

How have BIOL shares performed in 2024?

BIOLASE's stock was trading at $1.1220 on January 1st, 2024. Since then, BIOL stock has decreased by 87.2% and is now trading at $0.1438. View the best growth stocks for 2024 here .

When is BIOLASE's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our BIOL earnings forecast .

How were BIOLASE's earnings last quarter?

BIOLASE, Inc. (NASDAQ:BIOL) posted its quarterly earnings data on Thursday, March, 21st. The medical technology company reported ($1.76) earnings per share for the quarter. The medical technology company earned $13.49 million during the quarter. BIOLASE had a negative net margin of 41.97% and a negative trailing twelve-month return on equity of 555.22%.

When did BIOLASE's stock split?

Shares of BIOLASE reverse split before market open on Friday, July 28th 2023. The 1-100 reverse split was announced on Friday, July 28th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What guidance has BIOLASE issued on next quarter's earnings?

BIOLASE updated its first quarter 2024 earnings guidance on Thursday, March, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $10.0 million-, compared to the consensus revenue estimate of $10.8 million.

What is John R. Beaver's approval rating as BIOLASE's CEO?

4 employees have rated BIOLASE Chief Executive Officer John R. Beaver on Glassdoor.com . John R. Beaver has an approval rating of 13% among the company's employees. This puts John R. Beaver in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 35.0% of employees surveyed would recommend working at BIOLASE to a friend.

What other stocks do shareholders of BIOLASE own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BIOLASE investors own include Himax Technologies (HIMX) , Accelerate Diagnostics (AXDX) , Biocept (BIOC) , Magnachip Semiconductor (MX) , Fluidigm (FLDM) , Matinas BioPharma (MTNB) , MicroVision (MVIS) , Acasti Pharma (ACST) , Bionano Genomics (BNGO) and Genius Brands International (GNUS) .

How do I buy shares of BIOLASE?

Shares of BIOL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BIOL

BIOLASE (BIOL) Stock Price, News & Analysis

→ Nvidia Has a BIG Problem — Here’s Who Benefits MOST (From Weiss Ratings) (Ad)

Free BIOL Stock Alerts

$0.14

0.00 (-1.91%)

(As of 03:09 PM ET)

Compare

Today's Range: $0.14
▼
$0.15
50-Day Range: $0.13
▼
$0.50
52-Week Range: $0.13
▼
$47.10

Volume: 463,537 shs
Average Volume: 4.73 million shs
Market Capitalization: $4.69 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $77.00

Get BIOLASE alerts:

BIOLASE MarketRank™ Stock Analysis

Analyst Rating: 0.00 Rating Score
Upside/Downside: 53,446.6% Upside
$77.00 Price Target
Short Interest: Bearish
7.46% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.11 out of 5 stars

2.0

Analyst's Opinion

Amount of Analyst Coverage
BIOLASE has received no research coverage in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
7.46% of the float of BIOLASE has been sold short.
Short Interest Ratio / Days to Cover
BIOLASE has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in BIOLASE has recently increased by 692.66%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
BIOLASE does not currently pay a dividend.
Dividend Growth
BIOLASE does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BIOL.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 2 news articles for BIOLASE this week, compared to 1 article on an average week.
Search Interest
13 people have searched for BIOL on MarketBeat in the last 30 days. This is an increase of 225% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added BIOLASE to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BIOLASE insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.27% of the stock of BIOLASE is held by insiders.
Percentage Held by Institutions
Only 8.79% of the stock of BIOLASE is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of BIOLASE is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BIOLASE is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Weiss Ratings

Nvidia Has a BIG Problem — Here’s Who Benefits MOST

#1 AI Stock for 2024 Revealed In "AI Town Hall" This AI company just signed a deal with NVIDIA that went unreported by the media. Find out how you can get in on what is being dubbed 'the #1 AI stock for 2024 to buy now'

If You Missed Out On The AI Boom, Take These 3 Steps

About BIOLASE Stock (NASDAQ:BIOL)

BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode soft-tissue laser systems for soft tissue, hygiene, temporary pain relief, teeth whitening, and cosmetic procedures; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces; and sells teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Foothill Ranch, California.

BIOL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BIOL Stock News Headlines

April 18, 2024 | americanbankingnews.com

StockNews.com Initiates Coverage on BIOLASE (NASDAQ:BIOL)

April 17, 2024 | msn.com

BIOLASE (BIOL) Price Target Decreased by 19.68% to 11.45

April 18, 2024 | Weiss Ratings (Ad)

This Little-Known Stock Controls the Future of AI

April 10, 2024 | americanbankingnews.com

BIOLASE (NASDAQ:BIOL) Now Covered by StockNews.com

March 29, 2024 | markets.businessinsider.com

Celsius Holdings: Strong Buy on Robust Finances and Global Expansion Strategy

March 24, 2024 | marketwatch.com

Biolase Shares Jump 27% After Upbeat 2024 Revenue Guidance

March 23, 2024 | seekingalpha.com

BIOLASE, Inc. (BIOL) Q4 2023 Earnings Call Transcript

March 23, 2024 | markets.businessinsider.com

Biolase’s Strong Q4 Performance and Positive 2024 Outlook Affirm Buy Rating

April 18, 2024 | Weiss Ratings (Ad)

This Little-Known Stock Controls the Future of AI

March 23, 2024 | finance.yahoo.com

BIOLASE, Inc. (NASDAQ:BIOL) Q4 2023 Earnings Call Transcript

March 22, 2024 | markets.businessinsider.com

Why BIOLASE Shares Are Surging Friday

March 22, 2024 | finance.yahoo.com

Q4 2023 BIOLASE Inc Earnings Call

March 21, 2024 | benzinga.com

Recap: Biolase Q4 Earnings

March 21, 2024 | sfgate.com

Biolase: Q4 Earnings Snapshot

March 20, 2024 | benzinga.com

Earnings Preview For Biolase

February 23, 2024 | markets.businessinsider.com

Maxim Group Reaffirms Their Buy Rating on Biolase (BIOL)

February 22, 2024 | finanznachrichten.de

BIOLASE, Inc.: Biolase Launches State-of-the-Art All-Tissue Laser System To Accelerate Adoption of Lasers in Dentistry

February 22, 2024 | finance.yahoo.com

Biolase Launches State-of-the-Art All-Tissue Laser System To Accelerate Adoption of Lasers in Dentistry

February 21, 2024 | msn.com

The Toothbrush Storage Idea That Saves Valuable Counter Space In The Bathroom

February 20, 2024 | finanznachrichten.de

BIOLASE, Inc.: Biolase Announces First Quarter 2024 Webinar Series 'Lets Talk Dental'

February 20, 2024 | finance.yahoo.com

Biolase Announces First Quarter 2024 Webinar Series 'Lets Talk Dental'

February 15, 2024 | finance.yahoo.com

BIOLASE, Inc. Announces Closing of $7.0 Million Public Offering

February 14, 2024 | finance.yahoo.com

BIOLASE, Inc. Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement

February 13, 2024 | msn.com

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.35%

February 13, 2024 | msn.com

Gold Down Over 1%; Coca-Cola Posts Upbeat Sales

February 13, 2024 | finance.yahoo.com

BIOLASE, Inc. Announces Pricing of $7.0 Million Public Offering

January 29, 2024 | finanznachrichten.de

BIOLASE, Inc.: Biolase Reports Unaudited Revenue Growth For Full Year 2023 And Provides Outlook For Full Year 2024

See More Headlines

Receive BIOL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOLASE and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Dental equipment & supplies
Sub-Industry: N/A
Current Symbol: NASDAQ:BIOL
Previous Symbol: NASDAQ:BLTI
CUSIP: N/A
CIK: 811240
Web: www.biolase.com
Phone: (949) 361-1200
Fax: 949-273-6677
Employees: 157
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $77.00
High Stock Price Target: $150.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +53,335.1%
Consensus Rating
Rating Score (0-4): 0.00
Research Coverage: 0 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($32.58)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-20,630,000.00
Net Margins: -41.97%
Pretax Margin: -41.90%
Return on Equity: -555.22%
Return on Assets: -53.10%

Debt

Debt-to-Equity Ratio: 34.06
Current Ratio: 1.26
Quick Ratio: 0.68

Sales & Book Value

Annual Sales: $49.16 million
Price / Sales: 0.10
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.07) per share
Price / Book: -2.06

Miscellaneous

Outstanding Shares: 32,520,000
Free Float: 32,435,000
Market Cap: $4.69 million
Optionable: Not Optionable
Beta: 0.67

7 Stocks to Own Before the 2024 Election

Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.

Get This Free Report

Key Executives

Mr. John R. Beaver (Age 63)
President, CEO & Director
Comp: $377.53k
Ms. Jennifer Bright (Age 52)
Chief Financial Officer
Comp: $355.98k
Mr. Steven Sandor (Age 43)
Chief Operating Officer
Comp: $336.39k
Mr. Michael C. Carroll (Age 52)
Corporate Secretary

Key Competitors

View All Competitors

BIOL Stock Analysis - Frequently Asked Questions

What is BIOLASE's stock price target for 2024?: 0 equities research analysts have issued 1 year target prices for BIOLASE's stock. Their BIOL share price targets range from $4.00 to $150.00. On average, they anticipate the company's stock price to reach $77.00 in the next year. This suggests a possible upside of 53,446.6% from the stock's current price.
View analysts price targets for BIOL or view top-rated stocks among Wall Street analysts.
How have BIOL shares performed in 2024?: BIOLASE's stock was trading at $1.1220 on January 1st, 2024. Since then, BIOL stock has decreased by 87.2% and is now trading at $0.1438.
View the best growth stocks for 2024 here.
When is BIOLASE's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our BIOL earnings forecast.
How were BIOLASE's earnings last quarter?: BIOLASE, Inc. (NASDAQ:BIOL) posted its quarterly earnings data on Thursday, March, 21st. The medical technology company reported ($1.76) earnings per share for the quarter. The medical technology company earned $13.49 million during the quarter. BIOLASE had a negative net margin of 41.97% and a negative trailing twelve-month return on equity of 555.22%.
When did BIOLASE's stock split?: Shares of BIOLASE reverse split before market open on Friday, July 28th 2023. The 1-100 reverse split was announced on Friday, July 28th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 28th 2023. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

What guidance has BIOLASE issued on next quarter's earnings?: BIOLASE updated its first quarter 2024 earnings guidance on Thursday, March, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $10.0 million-, compared to the consensus revenue estimate of $10.8 million.
What is John R. Beaver's approval rating as BIOLASE's CEO?: 4 employees have rated BIOLASE Chief Executive Officer John R. Beaver on Glassdoor.com. John R. Beaver has an approval rating of 13% among the company's employees. This puts John R. Beaver in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 35.0% of employees surveyed would recommend working at BIOLASE to a friend.
What other stocks do shareholders of BIOLASE own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BIOLASE investors own include Himax Technologies (HIMX), Accelerate Diagnostics (AXDX), Biocept (BIOC), Magnachip Semiconductor (MX), Fluidigm (FLDM), Matinas BioPharma (MTNB), MicroVision (MVIS), Acasti Pharma (ACST), Bionano Genomics (BNGO) and Genius Brands International (GNUS).
How do I buy shares of BIOLASE?: Shares of BIOL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BIOL) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial